Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia

British Journal of Haematology

Volumn 130, Issue 2, 2005, Pages 196-202

  Kuchenbauer, Florian ^a,b   Schoch, Claudia ^a   Kern, Wolfgang ^a   Hiddemann, Wolfgang ^a,b   Haferlach, Torsten ^a   Schnittger, Susanne ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute promyelocytic leukaemia; Bcr; Event free survival; Flt3; Overall survival

Indexed keywords

ABELSON KINASE; FLT3 LIGAND; MIXED LINEAGE LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; BLOOD; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 24944447981     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05595.x     Document Type: Article

References (30)

1. Arrigoni, P., Beretta, C., Silvestri, D., Rossi, V., Rizzari, C., Valsecchi, M.G., Cazzaniga, G. & Biondi, A. (2003) FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology, 120, 89-92.
2. Awisati, G., Lo, C.F., Diverio, D., Falda, M., Ferrara, F., Lazzarino, M., Russo, D., Petti, M.C. & Mandelli, F. (1996) AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood, 88, 1390-1398.
3. Bagrintseva, K., Schwab, R., Kohl, T.M., Schnittger, S., Eichenlaub, S., Ellwart, J.W., Hiddemann, W. & Spiekermann, K. (2004) Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood, 103, 2266-2275.
4. Choppa, P.C., Gomez, J., Vall, H.G., Owens, M., Rappaport, H. & Lopategui, J.R. (2003) A novel method for the detection, quantitation, and breakpoint cluster region determination of t(15;17) fusion transcripts using a one-step real-time multiplex RT-PCR. American Journal of Clinical Pathology, 119, 137-144.
5. De Medeiros, B.C., Strapasson, E., Pasquini, R. & De Medeiros, C.R. (1998) Effect of all-trans retinoic acid on newly diagnosed acute promyelocytic leukemia patients: results of a Brazilian center. Brazilian Journal of Medical and Biological Research, 31, 1537-1543.
6. Evans, P., Jack, A., Short, M., Haynes, A., Shiach, C., Owen, R., Johnson, R. & Morgan, G.J. (1995) A single tube nested RT-PCR for detecting the common myeloid specific chromosomal translocations. Leukemia, 9, 1285-1286.
7. Gallagher, R.E., Li, Y.P., Rao, S., Paietta, E., Andersen, J., Etkind, P., Bennett, J.M., Tallman, M.S. & Wiernik, P.H. (1995) Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood, 86, 1540-1547.
8. Gallagher, R.E., Willman, C.L., Slack, J.L., Andersen, J.W., Li, Y.P., Viswanatha, D., Bloomfield, C.D., Appelbaum, F.R., Schiffer, C.A., Tallman, M.S. & Wiernik, P.H. (1997) Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood, 90, 1656-1663.
9. Gonzalez, M., Barragan, E., Bolufer, P., Chillon, C., Colomer, D., Borstein, R., Calasanz, M.J., Gomez-Casares, M.T., Villegas, A., Marugan, L, Roman, J., Martin, G., Rayon, C., Deben, G., Tormo, M., Diaz-Mediavilla, J., Esteve, J., Gonzalez-San Miguel, J., Rivas, C., Perez-Equiza, K., Garcia-Sanz, R., Capote, F.J., Ribera, J.M., Arias, J., Leon, A. & Sanz, M.A. (2001) Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. British Journal of Haematology, 114, 99-103.
10. Grimwade, D. & Lo, C.F. (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia, 16, 1959-1973.
11. Grimwade, D., Howe, K., Langabeer, S., Burnett, A., Goldstone, A. & Solomon, E. (1996) Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha- PML assessment in patients who ultimately relapse. Leukemia, 10, 61-66.
12. Gu, B.W., Xiong, H., Zhou, Y., Chen, B., Wang, L., Dong, S., Yu, Z.Y., Lu, L.F., Zhong, M., Yin, H.F., Zhu, G.F., Huang, W., Ren, S.X., Gallagher, R.E., Waxman, S., Chen, G.Q., Wang, Z.G., Chen, Z., Fu, G. & Chen, S.J. (2002) Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proceedings of the National Academy of Sciences of United States of America, 99, 7640-7645.
13. Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W. & Schoch, C. (2005) AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer, 43, 113-127.
14. Huang, W., Sun, G.L., Li, X.S., Cao, Q., Lu, Y., Jang, G.S., Zhang, F.Q., Chai, J.R., Wang, Z.Y. & Waxman, S. (1993) Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood, 82, 1264-1269.
15. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
16. Lengfelder, E., Reichert, A., Schoch, C., Haase, D., Haferlach, T., Loffler, H., Staib, P., Heyll, A., Seifarth, W., Saussele, S., Fonatsch, C., Gassmann, W., Ludwig, W.D., Hochhaus, A., Beelen, D., Aul, C., Sauerland, M.C., Heinecke, A., Hehlmann, R., Wormann, B., Hiddemann, W. & Buchner, T. (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia, 14, 1362-1370.
17. Libura, M., Asnafi, V., Tu, A., Delabesse, E., Tigaud, I., Cymbalista, F., Bennaceur-Griscelli, A., Villarese, P., Solbu, G., Hagemeijer, A., Beldjord, K., Hermine, O. & Macintyre, E. (2003) FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood, 102, 2198-2204.
18. Noguera, N.I., Breccia, M., Divona, M., Diverio, D., Costa, V., De Santis, S., Avvisati, G., Pinazzi, M.B., Petti, M.C., Mandelli, F. & Lo, C.F. (2002) Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 2185-2189.
19. Ozeki, K., Kiyoi, H., Hirose, Y., Iwai, M., Ninomiya, M., Kodera, Y., Miyawaki, S., Kuriyama, K., Shimazaki, C., Akiyama, H., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Ueda, R., Ohno, R., Emi, N. & Naoe, T. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 103, 1901-1908.
20. Reiter, A., Saussele, S., Grimwade, D., Wiemels, J.L., Segal, M.R., Lafage-Pochitaloff, M., Walz, C., Weisser, A., Hochhaus, A., Willer, A., Reichert, A., Buchner, T., Lengfelder, E., Hehlmann, R. & Cross, N.C. (2003) Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer, 36, 175-188.
21. Sanz, M.A., Lo, C.F., Martin, G., Avvisati, G., Rayon, C., Barbui, T., Diaz-Mediavilla, J., Fioritoni, G., Gonzalez, J.D., Liso, V., Esteve, J., Ferrara, F., Bolufer, P., Bernasconi, C., Gonzalez, M., Rodeghiero, F., Colomer, D., Petti, M.C., Ribera, J.M. & Mandelli, F. (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 96, 1247-1253.
22. Schnittger, S., Kinkelin, U., Schoch, C., Heinecke, A., Haase, D., Haferlach, T., Buchner, T., Wormann, B., Hiddemann, W. & Griesinger, F. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia, 14, 796-804.
23. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
24. Schnittger, S., Weisser, M., Schoch, C., Hiddemann, W., Haferlach, T. & Kern, W. (2003) New score predicting for prognosis in PML-RARA-, AML1-ETO-, or CBFB-MYH11- positive acute myeloid leukemia based on quantification of fusion transcripts. Blood, 102, 2746-2755.
25. Schoch, C. & Haferlach, T. (2002) Cytogenetics in acute myeloid leukemia. Current Oncological Reports, 4, 390-397.
26. Shih, L.Y., Kuo, M.C., Liang, D.C., Huang, CF., Lin, T.L., Wu, J.H., Wang, P.N., Dunn, P. & Lai, C.L. (2003) Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer, 98, 1206-1216.
27. Tallman, M.S., Nabhan, C., Feusner, J.H. & Rowe, J.M. (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, 99, 759-767.
28. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
29. Vahdat, L., Maslak, P., Miller, Jr, W.H., Eardley, A., Heller, G., Scheinberg, D.A. & Warrell, Jr, R.P. (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood, 84, 3843-3849.
30. Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S. & De The, H. (2005) A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 7, 143-153.